Hong Kong Stock Movement

GENSCRIPT BIO rose by 12.15%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Trading Volume in the Industry

WuXi AppTec rose by 11.17%. Based on recent key news:

1. On August 3, WuXi AppTec raised its full-year performance guidance for 2026, expecting revenue to be adjusted from RMB 51.3-53 billion to RMB 58.5-60.5 billion, with the growth rate of continuing operations revenue adjusted from 18%-22% to 35%-39%. This move exceeded market expectations and drove the stock price up. Source: Jinshi Data

2. On August 3, WuXi AppTec released its semi-annual report, showing that revenue for the first half of the year was RMB 28.897 billion, a year-on-year increase of 38.9%, and net profit was RMB 11.08 billion, a year-on-year increase of 33.7%. The strong performance further boosted market confidence. Source: Zhitong Finance

3. On August 4, Morgan Stanley maintained WuXi AppTec as its industry preferred stock, rating it "Overweight," with a target price of RMB 175, expecting the stock price to record an increase, supporting the rise in stock price. Source: Morgan Stanley

WuXi Biologics rose by 4.79%, with a trading volume of HKD 922 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

WuXi AppTec Holdings rose by 7.00%, with a trading volume of HKD 241 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Market Capitalization in the Industry

Crown Bioscience rose by 8.99%. Based on recent key news:

1. On August 3, Crown Bioscience's two business segments have yet to achieve profitability, increasing operational pressure. The revenue for macromolecule and cell and gene therapy services is projected to be RMB 475 million in 2025, with operating costs of RMB 666 million, resulting in a gross loss of RMB 191 million and a gross margin of -40.31%; in the first quarter of 2026, revenue is expected to decline by 11% year-on-year, with the gross margin dropping to -92.80%. The gross margin for clinical research services is expected to decline from 12.82% in 2024 to 11.41% in 2025, further dropping to 7.10% in the first quarter of 2026. The company attempts to build a comprehensive business map through mergers and acquisitions, but there are high technical and operational thresholds. The two loss-making businesses account for about 17% of total revenue, continuously consuming funds while diverting management's attention and the company's limited resources. Currently, the small molecule CDMO is at a critical window for expansion, requiring concentrated resource investment for capacity expansion and process team building, while CGT and clinical CRO businesses continue to divert resources. The debt structure is also a concern for the market; by the end of 2025, short-term loans are expected to reach RMB 1.265 billion, an increase of over 65% from the beginning of the year; non-current liabilities due within one year will reach RMB 3.624 billion, surging more than seven times from RMB 432 million at the beginning of the year, with the two liabilities totaling nearly RMB 4.9 billion The company explained that the main reason is the reclassification of long-term loans as current liabilities due within one year. Regardless of the cause, the scale of debt that the company needs to repay or refinance in 2026 has significantly increased compared to the previous year. Policy catalysts have driven a recovery in sentiment within the CXO sector, and the high growth in CDMO orders has brought expectations for performance growth. However, the sustainability of this rebound largely depends on whether profit growth can keep pace with revenue growth. The global biotech financing environment is recovering, new orders are accelerating, and the proportion of CDMO business is continuously increasing, indicating signs of operational recovery; however, challenges also objectively exist: the laboratory business supported by 25,000 R&D personnel remains the foundation, and improvements in labor efficiency are not yet evident; the 3.5 billion yuan goodwill remains unresolved, and the two major business segments continue to incur losses; the scale of short-term debt repayment has significantly increased, creating multiple pressures. The CXO industry has distinct cyclical attributes, and during the upward phase of the financing environment, companies within the sector generally experience valuation recovery; when the financing boom fades, the quality of profits becomes the core metric for assessing corporate value. For Kanglong Chemical to achieve a true reversal from stock price rebound to fundamental improvement, merely having order growth is far from sufficient. The company needs to demonstrate that early projects undertaken by the laboratory can continuously convert into scaled CDMO revenue, and navigate through cost pressures and potential goodwill risks, ultimately reflecting as sustained improvement in net profit. From this perspective, Kanglong Chemical still faces numerous challenges ahead. The CXO industry has distinct cyclical attributes, and during the upward phase of the financing environment, companies within the sector generally experience valuation recovery